Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608528 · ClinicalTrials.gov registry record
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- 10
- Enrollment target
NCT02608528 is a clinical trial that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants.
The verdict
NCT02608528 was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overall survival.
Interventions
- RADIATION [18F]fluoroglucose(FDG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10-22 |
| Est. Completion | 2019-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608528
The ClinicalTrials.gov registry entry for NCT02608528 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]fluoroglucose(FDG) is the first listed.
NCT02608528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608528 about?
NCT02608528 is a clinical study titled "Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy". Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overa...
What is the current status of trial NCT02608528?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2015-10-22. Estimated completion is 2019-07-18.
What interventions are being tested in trial NCT02608528?
The interventions under investigation include: [18F]fluoroglucose(FDG) (RADIATION).
Who is sponsoring clinical trial NCT02608528?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.